Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
Go back to Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy| Veramark Technologies, Inc. (NASDAQ: VERA) | Delayed: 35.51 -0.84 (2.31%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.35 | 52 Week High | $1.18 | |||
| Open | $36.69 | 52 Week Low | $0.36 | |||
| Day High | $36.87 | P/E | 591.83 | |||
| Day Low | $35.44 | EPS | $0.06 | |||
| Volume | 359,969 | |||||
